Monitoring of methylation changes in 9p21 region in patients with myelodysplastic syndromes and acute myeloid leukemia

Neoplasma

Volumn 59, Issue 2, 2012, Pages 168-174

  Cechova, H ^a   Lassuthova, P ^a   Novakova, L ^a   Belickova, M ^a   Stemberkova, R ^a   Jencik, J ^a   Stankova, M ^a   Hrabakova, P ^a   Pegova, K ^a   Zizkova, H ^a   Cermak, J ^a  

^a INSTITUTE OF HEMATOLOGY AND BLOOD TRANSFUSION   (Czech Republic)

Author keywords

5 azacytidine; CDKN2A; CDKN2B; DNA methylation; MS MLPA

Indexed keywords

AZACITIDINE; CDKN2B PROTEIN, HUMAN; CYCLIN DEPENDENT KINASE INHIBITOR 2A; CYCLIN DEPENDENT KINASE INHIBITOR 2B; DNA;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; CDKN2B GENE; CONTROLLED STUDY; CPG ISLAND; DEMETHYLATION; DISEASE COURSE; DNA METHYLATION; FEMALE; GENE; HUMAN; INTERNATIONAL PROGNOSTIC SCORING SYSTEM; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; MULTIPLEX LIGATION DEPENDENT PROBE AMPLIFICATION; MYELODYSPLASTIC SYNDROME; PERIPHERAL BLOOD MONONUCLEAR CELL; POLYMERASE CHAIN REACTION; REMISSION; WORLD HEALTH ORGANIZATION; CASE CONTROL STUDY; CELL TRANSFORMATION; COMPARATIVE STUDY; GENETICS; MIDDLE AGED; PROGNOSIS;

ADULT; AGED; CASE-CONTROL STUDIES; CELL TRANSFORMATION, NEOPLASTIC; CYCLIN-DEPENDENT KINASE INHIBITOR P15; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DISEASE PROGRESSION; DNA; DNA METHYLATION; FEMALE; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; POLYMERASE CHAIN REACTION; PROGNOSIS; YOUNG ADULT;

EID: 84863848051     PISSN: 00282685     EISSN: 13384317     Source Type: Journal    
DOI: 10.4149/neo_2012_022     Document Type: Article

References (29)

1. ISSA JP, KANTARJIAN HM. Targeting DNA methylation. Clin Cancer Res. 2009 Jun 15; 15(12): 3938-46. http://dx.doi. org/10.1158/1078-0432.CCR-08-2783
2. AGRAWAL S, UNTERBERG M, KOSCHMIEDER S, ZUR STADT U, BRUNNBERG U et al. DNA methylation of tumor suppressor genes in clinical remission predicts the relapse risk in acute myeloid leukemia. Cancer Res. 2007 Feb 1; 67(3): 1370-7. http://dx.doi.org/10.1158/0008-5472.CAN-06-1681
3. CAIAFA P, ZAMPIERI M. DNA methylation and chromatin structure: the puzzling CpG islands. J Cell Biochem. 2005 Feb 1; 94(2): 257-65. Review. http://dx.doi.org/10.1002/jcb.20325
4. HERMAN JG, GRAFF JR, MYÖHÄNEN S, NELKIN BD, BAYLIN SB. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci U S A. 1996 Sep 3; 93(18): 9821-6.
5. ESTELLER M, HERMAN JG. Cancer as an epigenetic disease: DNA methylation and chromatin alterations in human tumours. J Pathol. 2002 Jan; 196(1): 1-7. Review. http://dx.doi. org/10.1002/path.1024
6. MERLO A, HERMAN JG, MAO L, LEE DJ, GABRIELSON E et al. 5' CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers. Nat Med. 1995 Jul; 1(7): 686-92. http://dx.doi.org/10.1038/nm0795-686
7. TIEN HF, TANG JH, TSAY W, LIU MC, LEE FY et al. Methylation of the p15(INK4B) gene in myelodysplastic syndrome: it can be detected early at diagnosis or during disease progression and is highly associated with leukaemic transformation. Br J Haematol. 2001 Jan; 112(1): 148-54. http://dx.doi. org/10.1046/j.1365-2141.2001.02496.x
8. SOLOMON PR, MUNIRAJAN AK, TSUCHIDA N, MUTHUKUMARASAMY K, RATHINAVEL A et al. Promoter hypermethylation analysis in myelodysplastic syndromes: diagnostic & prognostic implication. Indian J Med Res. 2008 Jan; 127(1): 52-7.
9. CHRISTMAN JK. 5-Azacytidine and 5-aza-2'-deoxycytidine as inhibitors of DNA methylation: mechanistic studies and their implications for cancer therapy. Oncogene. 2002 Aug 12; 21(35): 5483-95. Review. http://dx.doi.org/10.1038/sj.onc.1205699
10. MALCOVATI L, NIMER SD. Myelodysplastic syndromes: diagnosis and staging. Cancer Control. 2008 Oct;15 Suppl:4-13. Review.
11. UCHIDA T, KINOSHITA T, NAGAI H, NAKAHARA Y, SAITO H et al. Hypermethylation of the p15INK4B gene in myelodysplastic syndromes. Blood. 1997 Aug 15; 90(4): 1403-9.
12. NIMER SD. Myelodysplastic syndromes. Blood. 2008 May 15; 111(10): 4841-51. Review. http://dx.doi.org/10.1182/blood-2007-08-078139
13. VARDIMAN JW, THIELE J, ARBER DA, BRUNNING RD, BOROWITZ MJ et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009 Jul 30; 114(5): 937-51. http://dx.doi.org/10.1182/blood-2009-03-209262
14. WEINBERG OK, SEETHARAM M, REN L, SEO K, MA L et al. Clinical characterization of acute myeloid leukemia with myelodysplasia-related changes as defined by the 2008 WHO classification system. Blood. 2009 Feb 26; 113(9): 1906-8. http://dx.doi.org/10.1182/blood-2008-10-182782
15. FENAUX P, MUFTI GJ, HELLSTROM-LINDBERG E, SANTINI V, FINELLI C et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, openlabel, phase III study. Lancet Oncol. 2009 Mar; 10(3): 223-32. http://dx.doi.org/10.1016/S1470-2045(09)70003-8
16. SANTINI V. Azacitidine in lower-risk myelodysplastic syndromes. Leuk Res. 2009 Dec;33 Suppl 2: S22-6. http://dx.doi. org/10.1016/S0145-2126(09)70230-9
17. TEFFERI A. Myelodysplastic syndromes--many new drugs, little therapeutic progress. Mayo Clin Proc. 2010 Nov;85(11):1042-5. http://dx.doi.org/10.4065/mcp.2010.0502
18. VIGIL CE, MARTIN-SANTOS T, GARCIA-MANERO G. Safety and efficacy of azacitidine in myelodysplastic syndromes. Drug Des Devel Ther. 2010 Sep 24; 4: 221-9. Review.
19. MILLER SA, DYKES DD, POLESKY HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res. 1988 Feb 11; 16(3): 1215. http://dx.doi. org/10.1093/nar/16.3.1215
20. NYGREN AO, AMEZIANE N, DUARTE HM, VIJZELAAR RN, WAISFISZ Q et al. Methylation-specific MLPA (MSMLPA): simultaneous detection of CpG methylation and copy number changes of up to 40 sequences. Nucleic Acids Res. 2005 Aug 16; 33(14): e128. http://dx.doi.org/10.1093/nar/gni127
21. HERMAN JG, CIVIN CI, ISSA JP, COLLECTOR MI, SHARKIS SJ et al. Distinct patterns of inactivation of p15INK4B and p16INK4A characterize the major types of hematological malignancies. Cancer Res. 1997 Mar 1; 57(5): 837-41.
22. AGGERHOLM A, HOLM MS, GULDBERG P, OLESEN LH, HOKLAND P. Promoter hypermethylation of p15INK4B, HIC1, CDH1, and ER is frequent in myelodysplastic syndrome and predicts poor prognosis in early-stage patients. Eur J Haematol. 2006 Jan; 76(1): 23-32. http://dx.doi.org/10.1111/j.1600-0609.2005.00559.x
23. HERMAN JG, JEN J, MERLO A, BAYLIN SB. Hypermethylation-associated inactivation indicates a tumor suppressor role for p15INK4B. Cancer Res. 1996 Feb 15; 56(4): 722-7.
24. VASIKOVA A, BELICKOVA M, BUDINSKA E, CERMAK J. A distinct expression of various gene subsets in CD34+ cells from patients with early and advanced myelodysplastic syndrome. Leuk Res. 2010 Dec; 34(12): 1566-1572. http://dx.doi. org/10.1016/j.leukres.2010.02.021
25. FANDY TE, HERMAN JG, KERNS P, JIEMJIT A, SUGAR EA et al. Early epigenetic changes and DNA damage do not predict clinical response in an overlapping schedule of 5-azacytidine and entinostat in patients with myeloid malignancies. Blood. 2009 Sep 24; 114(13): 2764-73.
26. RAJ K, JOHN A, HO A, CHRONIS C, KHAN S et al. CDKN2B methylation status and isolated chromosome 7 abnormalities predict responses to treatment with 5-azacytidine. Leukemia. 2007 Sep; 21(9): 1937-44. http://dx.doi. org/10.1038/sj.leu.2404796
27. TRAN HT, KIM HN, LEE IK, KIM YK, AHN JS et al. DNA methylation changes following 5-azacitidine treatment in patients with myelodysplastic syndrome. J Korean Med Sci. 2011 Feb; 26(2): 207-13. http://dx.doi.org/10.3346/jkms.2011.26.2.207
28. GRAEF T, KUENDGEN A, FENK R, ZOHREN F, HAAS R et al. Successful treatment of relapsed AML after allogeneic stem cell transplantation with azacitidine. Leuk Res. 2007 Feb; 31(2): 257-9. http://dx.doi.org/10.1016/j.leukres.2006.03.003
29. JABBOUR E, GIRALT S, KANTARJIAN H, GARCIA-MANERO G, JAGASIA M et al. Low-dose azacitidine after allogeneic stem cell transplantation for acute leukemia. Cancer. 2009 May 1; 115(9): 1899-905. http://dx.doi.org/10.1002/cncr.24198